Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals provided a business update and reported a net loss of $8.0 million for the second quarter of 2025. The company reported third-quarter 2025 financial results with earnings per share (EPS) of -$0.12, exceeding analysts' expectations. Corvus Pharmaceuticals announced positive results from Cohort 4 of its Phase 1 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis, leading to a significant surge in CRVS shares. Following the encouraging clinical trial results, Corvus Pharmaceuticals announced the pricing of an upsized public offering of common stock. The company announced the closing of its upsized public offering of common stock, generating gross proceeds of approximately $201 million. Corvus Pharmaceuticals' price target was increased by 128.26% to $35.70, and the share price as of February 5, 2026, was $19.06, representing a 253.62% increase over the past year.

As a clinical-stage biopharmaceutical company, Corvus Pharmaceuticals, Inc. does not currently have commercialized products on the market that would be subject to typical consumer demand seasonality. The company's revenue generation is primarily dependent on regulatory approvals and the subsequent market penetration of its drug candidates. Therefore, there is no readily available information indicating demand seasonality for Corvus Pharmaceuticals' products and services.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies within the Healthcare sector, specifically in the Biotechnology and Drugs industry, aiming to develop novel therapies to significantly improve the treatment of immune diseases and cancer. The company's lead product candidate, Soquelitinib (CPI-818), is being evaluated in a Phase 3 clinical trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and in a Phase 1 clinical trial for moderate-to-severe atopic dermatitis, asthma, psoriasis, and fibrotic diseases. Ciforadenant (CPI-444) is in a Phase 2 clinical trial for the treatment of metastatic renal cell cancer. Mupadolimab (CPI-006) is in a Phase 1b clinical trial for the treatment of non-small cell lung cancer, and Corvus Pharmaceuticals has a strategic collaboration with Angel Pharmaceuticals Co. Ltd. for its development and commercialization.

Corvus Pharmaceuticals, Inc. is based in South San Francisco, California, United States, and engages in the development of product candidates in the United States. The company has a strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab, indicating an international partnership.

Corvus Pharmaceuticals' brand reputation has been positively influenced by its clinical advancements and financial activities, including positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis, analyst upgrades, and the closing of an upsized public offering in January 2026. There is no readily available information indicating any significant negative events that have adversely affected Corvus Pharmaceuticals, Inc.'s brand reputation in the past year.

Corvus Pharmaceuticals, Inc. has 180 institutional owners and shareholders holding a total of 45,009,487 shares, including Orbimed Advisors Llc, Point72 Asset Management, L.P., and BlackRock, Inc. As of January 28, 2026, Caduceus Private Investments V, L.P. and OrbiMed Advisors LLC each held 10.28% of the holding.